199 related articles for article (PubMed ID: 38124057)
21. [Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
Wójcik B; Kowalczyk JR; Chybicka A; Wachowiak J; Drabko K; Zaucha-Prazmo A; Choma M; Gorczyńska E; Toporski J; Turkiewicz D; Kałwak K; Pieczonka A; Boruczkowski D
Przegl Lek; 2004; 61 Suppl 2():53-6. PubMed ID: 15686047
[TBL] [Abstract][Full Text] [Related]
22. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Alkhaldi H; Reinhardt A; Barnett M; Kundu S; Hosing C; Ramdial J; Saini N; Srour S; Alousi A; Kebriaei P; Popat U; Qazilbash M; Champlin R; Shpall EJ; Gulbis A; Shigle TL; Dabaja B; Pinnix C; Ahmed S; Steiner R; Andersson BS; Nieto Y
Transplant Cell Ther; 2023 Nov; 29(11):690-694. PubMed ID: 37607645
[TBL] [Abstract][Full Text] [Related]
23. [Dose-intensive immunochemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of 29 newly diagnosed young patients with medium/high risk diffuse large B-cell lymphoma].
Yi S; Liu W; Lyu R; Li Z; Xu Y; Sui W; Huang W; Wang T; Deng S; Liu H; Fu M; Zou D; Qiu L
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):546-50. PubMed ID: 24985182
[TBL] [Abstract][Full Text] [Related]
24. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
[TBL] [Abstract][Full Text] [Related]
25. Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma.
Kim YR; Yoon SO; Kim SJ; Cheong JW; Chung H; Lee JY; Jang JE; Kim Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2020 Sep; 99(9):2149-2157. PubMed ID: 32390113
[TBL] [Abstract][Full Text] [Related]
26. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J
Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
Sirohi B; Cunningham D; Powles R; Murphy F; Arkenau T; Norman A; Oates J; Wotherspoon A; Horwich A
Ann Oncol; 2008 Jul; 19(7):1312-1319. PubMed ID: 18356139
[TBL] [Abstract][Full Text] [Related]
28. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
29. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells.
Landsburg DJ; Nasta SD; Svoboda J; Gerson JN; Schuster SJ; Barta SK; Chong EA; Difilippo H; Weber E; Cunningham K; Catania C; Garfall AL; Stadtmauer EA; Frey NV; Porter DL
Transplant Cell Ther; 2023 Aug; 29(8):495-503. PubMed ID: 37211154
[TBL] [Abstract][Full Text] [Related]
30. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
Ann Oncol; 2004 Dec; 15(12):1790-7. PubMed ID: 15550584
[TBL] [Abstract][Full Text] [Related]
31. Disease characteristics of diffuse large B-cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience.
Gaut D; Romero T; Oveisi D; Howell G; Schiller G
Hematol Oncol; 2020 Feb; 38(1):38-50. PubMed ID: 31674036
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
33. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
35. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.
Ban-Hoefen M; Kelly JL; Bernstein SH; Liesveld J; Constine L; Becker M; Milner L; Phillips G; Friedberg JW
Leuk Lymphoma; 2012 May; 53(5):830-5. PubMed ID: 22023518
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
[TBL] [Abstract][Full Text] [Related]
37. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.
Kuruvilla J; MacDonald DA; Kouroukis CT; Cheung M; Olney HJ; Turner AR; Anglin P; Seftel M; Ismail WS; Luminari S; Couban S; Baetz T; Meyer RM; Hay AE; Shepherd L; Djurfeldt MS; Alamoudi S; Chen BE; Crump M
Blood; 2015 Aug; 126(6):733-8. PubMed ID: 26109202
[TBL] [Abstract][Full Text] [Related]
38. The efficacy and safety of autologous stem cell transplantation in relapsed chemosensitive and chemoresistant patients with diffuse large B-cell lymphoma.
Armatys A; Wieczorkiewicz-Kabut A; Panz-Klapuch M; Koclega A; Kopinska AJ; Kata D; Wozniczka K; Helbig G
Neoplasma; 2020 Nov; 67(6):1431-1436. PubMed ID: 32701355
[TBL] [Abstract][Full Text] [Related]
39. Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Lee YS; Liu J; Fricano KA; Webb EM; Toolsie DR; Jones S; Rhoads JA; Vij R; Cashen AF; Abboud CN; Westervelt P; Bartlett NL; Dipersio JF; Kreisel FH; Lim KH
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2199-2204. PubMed ID: 28847710
[TBL] [Abstract][Full Text] [Related]
40. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]